NEW YORK, Jan 29 - Incyte and UK-based Oxagen have announced a collaboration, in which the two companies will jointly investigate genes related to osteoporosis for drug target validation and discovery, and Oxagen will receive access to Incyte’s LifeSeq gold database for use in its disease areas, the companies announced Monday.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.